Clik here to view.
Canaccord Genuity starts TearLab at buy
Canaccord Genuity has initiated coverage of TearLab (NASDAQ:TEAR; TSX:TLB) with a “buy” rating and $6 price target, saying the company offers the first point-of-care instrument that can quantitatively...
View ArticleClik here to view.
Survey shows big DED opportunity for TearLab
Canaccord Genuity has conducted a survey with 34 U.S. ophthalmologists about dry eye disease (DED), which “supports a meaningful opportunity for TearLab (NASDAQ:TEAR; TSX:TLB),” and its osmolarity...
View ArticleClik here to view.
In conversation with Jeffrey Frelick
Jeffrey Frelick’s road to Wall Street began as a laboratory technologist with Clinical Pathology Facility before he joined Becton Dickinson in 1991 as a sales representative and regional sales manager....
View ArticleClik here to view.
Canaccord ups TearLab price target to $8
Canaccord Genuity has raised its price target on “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $8 from $6, saying the growth profile of the stock justifies a higher multiple than its peer group. The...
View ArticleClik here to view.
Craig-Hallum, Canaccord up TearLab price targets
Craig-Hallum Capital Group and Canaccord Genuity raised their price targets for “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) after the company pre-announced second quarter revenues and system order...
View ArticleClik here to view.
Venaxis pivotal APPY1 data due in March
Venaxis (NASDAQ:APPY) expects to report top-line data in March from a pivotal study of its rapid, protein biomarker-based assay for appendicitis, the APPY1 Test and, depending on the results, submit a...
View Article
